The Editors
Zachary T. Bloomgarden, MD
Dr. Bloomgarden has a national reputation for writing and lecturing on diabetes. He is Clinical Professor at the Mount Sinai School of Medicine, a member of the Board of the American Association of Clinical Endocrinologists, and served on the Journals Managing Subcommittee of the Endocrine Society. He has worked in the American Diabetes Association as a member of the Editorial Board, and subsequently as an Associate Editor of the clinical journal, Diabetes Care, and has over the past twelve years written the monthly “Perspectives on the News” column for this publication, a widely read and respected summary of current developments in the field, now available as an online CME activity. Dr. Bloomgarden has lectured nationally and internationally and has acted as an advisor for a number of pharmaceutical groups. He is an honorary professor at the Biocor Hospital de Doenças Cardiovasculares, Belo Horizonte, Brazil. He has been principal investigator in numerous studies, assessing treatment with troglitazone, glyburide, insulin, metformin, glimepiride, glipizide, fluvastatin, dichloroacetate, sildenafil, and patient education. In his successful clinical practice, Dr. Bloomgarden is one of the best well-known diabetologists in New York, and is listed in the “Castle Connolly Guide: The Best Doctors New York Metro Area.”
Ning Guang, MD
Andrew J. Drexler, MD
Youfei Guan, MD, PhD
Dr. Guan has an international reputation in the field of renal physiology, blood pressure regulation and diabetic nephropathy. His research interest is mainly focusing on therapeutic targeting of prostaglandin E2 receptors such as the EP1, EP2, EP3 and EP4 receptors and metabolic nuclear receptors including peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs) and farnesoid X receptor (FXR) in diabetes, hypertension, lipid metabolism disorder, obesity and related renal complications. He has published more than 60 peer-reviewed articles in many journals including Nature Medicine, Journal of Clinical Investigation, Kidney International and American Journal of Physiology. His research has been supported by NIDDK (RO1), NNSFC, the Ministry of Education of China, the Ministry of Science and Technology of China and Pharmaceutical industry. He served as an associate editor or member of the editorial board of many journals including Kidney International, Biochemical Journal, PPAR Research and Chinese Journal of Diabetes. Dr. Guan has given a number of lectures nationally and internationally and has acted as a consultant for several pharmaceutical companies. He was named a Changjiang Scholar by the Ministry of Education of China and is currentl y the Chair of Department of Physiology and Pathophysiology at Peking (Beijing) University Health Science Center, and the Co-director of Peking (Beijing) Univer sity Diabetes Center.
Yehuda Handelsman, MD, FACP, FACE
Yehuda Handelsman, MD, FACP, FACE, is an endocrinologist in solo private practice in Tarzana, California, where he developed and successfully utilizes a comprehensive and unique, multiple interventions, method to preventing cardiovascular disease in the high risk patient. He is Medical Director of the Metabolic Institute of America”, Principal Investigator of its clinical research division and clinical investigator at the Westside Arthritis & Metabolism Center. He is Senior Scientific Consultant for the Metabolic Endocrine Education Foundation. Dr Handelsman is Chair and founder of the International Committee for Insulin Resistance; and Chair and Program Director of the Annual World Congress on the Insulin Resistance Syndrome. Dr. Handelsman is secretary and executive board member of the American Association of Clinical Endocrinology (AACE), where he has been a national board member since 2002 and served as a trustee of the American College of Endocrinology for 2 years. Currently he serves on AACE’s National Lipids Guidelines Task Force, Diabetes road map task force, a task force to create standards for insulin pumps and the American College of Endocrinology task force on the Prevention of Diabetes where he is co chair for programming. He has been a member of the 2007 Diabetes Guidelines Revision Committee, and a reviewer for the HTN guideline. Additionally he serves as associate Editor, “Journal of Diabetes” an International peer reviewed journal, based in China, devoted to diabetes research, therapeutics and education; and he is on the editorial board of “Clinical Endocrine News”.
Dr. Handelsman is a summa cum laude graduate of the University of the Pacific, in Stockton, California. A Fellow of the American College of Endocrinology and the American College of Physicians, he earned his doctor of medicine degree from Tel Aviv University Sackler Faculty of Medicine in Tel Aviv, Israel. He completed a subsequent internship and residency in internal medicine at New York Infirmary Beekman Downtown Hospital under the auspices of New York University. His fellowship in diabetes and endocrinology was conducted at the University of Southern California Medical School in Los Angeles
He is a member of such professional organizations as American Association of Clinical Endocrinology, the American Diabetes Association, National Lipid Association, American Thyroid Association, Academy of Thyrodologists, American college of Physicians, Los Angeles and California Medical Associations and the American Medical Association. Dr. Handelsman is a frequent lecturer, both nationally and internationally, on such metabolic topics as diabetes, hypertension, lipids disorders, insulin resistance, metabolic syndromes and prevention of cardiovascular disease, obesity, thyroid and osteoporosis.
Xiaoying Li, MD
Xiaoying Li, MD, PhD. Professor, Department of Endocrinology and Metabolism, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine. Deputy Director of Shanghai Institute of Endocrinology and Metabolism. Dr. Li obtained his MD from Heng Yang Medical College in 1983 and Ph.D from Shanghai Second Medical University in 1996. He was trained as a postdoctoral fellow in Baylor College of Medicine, USA in 1998-2000 and in McGill University, Canada in 2000-2003. His major research interest is focused on molecular mechanism of insulin resistance and intervention of type 2 diabetes with natural compounds from TMC. He has published 34 scientific papers in international journals.
Jianmin Liu, MD
Dr Jian-Min Liu is the Chief Physician in the Dept. of Endocrinology and Metabolism, Shanghai Rui-Jin Hospital, a well known hospital in China. He is also the clinical professor of endocrinology in Shanghai Jiao-Tong University Medical School. With its outstanding performance, the Dept of Endocrinology is appointed as Shanghai Clinical Center for Endocrine and Metabolic Diseases by the Shanghai municipality, and Dr. Liu is the Vice Chief since 2002. His other academic activities include the President in the Society of Osteoporosis, Chinese Medical Association, Shanghai branch; committee member in the Society of Osteoporosis and Metabolic Bone Diseases, the Chinese Medical Association; and editorial board member in the Chinese Journal of Endocrinology and Metabolism. He finished his postdoctoral research in Columbia University College of Physicians and Surgeons after earning his Ph.D. in internal medicine from Shanghai Second Medical University. His current research interests focus on diabetes, osteoporosis and postmenopause.